Efficient and novel multidomain feature analysis model with incremental optimizations for enhancing pediatric myelodysplastic syndrome detection

Abstract

Pediatric myelodysplastic syndromes (MDS) are complicated, thus early and accurate diagnosis is essential for treatment planning and patient care. Diagnostic processes often use discrete data domain analysis, which reduces accuracy and delays diagnosis. This work addresses these limitations by introducing an advanced Multi domain Feature Analysis Model (MFAM) enhanced with incremental optimizations to improve pediatric MDS detection. Traditional pediatric MDS diagnosis relies on subjective evaluations and limited data fusion, not modern computational methods. These constraints may reduce diagnosis accuracy and postpone action. The proposed MFAM integrates data from Clinical History, Physical Examination, Blood Cell Counts, Peripheral Blood Smear, Bone Marrow Aspiration and Biopsy, Cytogenetic Analysis, Flow Cytometry, Genetic Testing, Iron Studies, and Bone Marrow Cytology to overcome these challenges. The MFAM increases feature variance by fusing Bidirectional Long Short-Term Memory (BiLSTM) with Bidirectional Gated Recurrent Units (BiGRU). Deep Q Learning with Graph Recurrent Convolutional Neural Networks (DQGRCNN) boosts efficiency. Additionally, the model integrates the Vector Autoregressive Moving Average with Exogenous Inputs (VARMAX) to facilitate early prediction of paediatric MDS. These enhancements have resulted in significant improvements in the precision of paediatric MDS detection by 4.5%, accuracy by 3.5%, recall by 2.3%, Area Under the Curve (AUC) by 1.5%, and specificity by 2.4% while reducing diagnostic delays by 8.5%. Furthermore, the model enhances the precision of predictive analysis by 2.9%, accuracy by 3.5%, recall by 2.5%, AUC by 2.9%, specificity by 5.5%, and reduces delays in predictive analysis by 8.5%. The MFAM presented in this paper revolutionizes the diagnosis and treatment of paediatric MDS by efficiently combining diverse diagnostic data, employing advanced transformation and fusion techniques, and optimizing responses through DQGRCNN. The integration of VARMAX further enables early prediction of the disease. MFAM will enhance diagnostic precision, therapy start, and clinical outcomes for young MDS patients.